Some anti-CD24 drugs targeting tumors have been put into clinical trials, such as SWA11 (mAb), which is related to ovarian cancer and pancreatic cancer, and rG7S-MICA (mAb), which is related to liver cancer. Here, CD24 is linked to ovarian carcinoma.